{"created":"2022-02-22T07:18:42.760268+00:00","id":2016892,"links":{},"metadata":{"_buckets":{"deposit":"ab301a5f-d81a-46ed-bc18-8ca9fa5ccdb5"},"_deposit":{"id":"2016892","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"2016892"},"status":"published"},"_oai":{"id":"oai:u-ryukyu.repo.nii.ac.jp:02016892","sets":["1642838163960:1642838198944:1642838199408:1642838231050","1642838403551:1642838412624"]},"author_link":[],"item_30002_access_rights4":{"attribute_name":"Access Rights","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_30002_bibliographic_information29":{"attribute_name":"Bibliographic Information","attribute_value_mlt":[{"bibliographicIssueNumber":"1-2","bibliographicPageEnd":"28","bibliographicPageStart":"25","bibliographicVolumeNumber":"36"}]},"item_30002_creator2":{"attribute_name":"Creator","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Nagayama-Urasoe, Chiaki","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Umikawa, Masato","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Asato, Tsuyoshi","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Nagai, Yutaka","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Aoki, Yoichi","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Kariya, Ken-ichi","creatorNameLang":"en"}]}]},"item_30002_description9":{"attribute_name":"Description","attribute_value_mlt":[{"subitem_description":"Patient-derived xenograft (PDX) models are useful for preclinical evaluation of anticancer agents. However, establishing PDX models of cervical cancers are known to be challenging. We modified a protocol from the existing literature and established a model of an HPV16-positive squamous cell carcinoma on scid mice. The xenograft was positive for p16INK4a even after a passage, indicating the continued involvement of the E7 viral oncoprotein in abnormal cell growth. After 24 days of treatment with a nucleoside analog, gemcitabine, tumor growth was found to be suppressed in a dose-dependent manner, and the tumor became undetectable after high-dose treatment. Cediranib, an orally bioavailable inhibitor of neovascularization, reversed tumor growth until it was barely detectable. A hydrophobic cancer stem cell inhibitor, salinomycin, did not show any significant effect when used alone, but showed a tendency to act synergistically with low-dose gemcitabine. Although further procedural refinements are required, the model appeared to be useful for preclinical evaluation of various anticancer agents, including novel ones that target specific molecules.","subitem_description_type":"Other"},{"subitem_description":"論文","subitem_description_type":"Other"}]},"item_30002_file35":{"attribute_name":"File","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","filename":"v36(1-2)p25.pdf","mimetype":"application/pdf","url":{"objectType":"fulltext","url":"https://u-ryukyu.repo.nii.ac.jp/record/2016892/files/v36(1-2)p25.pdf"},"version_id":"44bc92f8-bf1e-47ec-bfea-ccca8baa3996"}]},"item_30002_language12":{"attribute_name":"Language","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_30002_publisher10":{"attribute_name":"Publisher","attribute_value_mlt":[{"subitem_publisher":"琉球医学会","subitem_publisher_language":"ja"},{"subitem_publisher":"Ryukyu Medical Association","subitem_publisher_language":"en"}]},"item_30002_resource_type13":{"attribute_name":"Resource Type","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_30002_rights6":{"attribute_name":"Rights","attribute_value_mlt":[{"subitem_rights":"琉球医学会","subitem_rights_language":"ja"}]},"item_30002_source_identifier22":{"attribute_name":"Source Identifier","attribute_value_mlt":[{"subitem_source_identifier":"1346-888X","subitem_source_identifier_type":"ISSN"},{"subitem_source_identifier":"AN10369445","subitem_source_identifier_type":"NCID"}]},"item_30002_source_title23":{"attribute_name":"Source Title","attribute_value_mlt":[{"subitem_source_title":"琉球医学会誌 = Ryukyu Medical Journal","subitem_source_title_language":"ja"}]},"item_30002_subject8":{"attribute_name":"Subject","attribute_value_mlt":[{"subitem_subject":"cervical cancer","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"patient-derived xenograft","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"gemcitabine","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"cediranib","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"salinomycin","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_30002_title0":{"attribute_name":"Title","attribute_value_mlt":[{"subitem_title":"Evaluation of candidate therapies using a patient-derived cervical cancer xenograft model","subitem_title_language":"en"}]},"item_30002_version_type15":{"attribute_name":"Version Type","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_title":"Evaluation of candidate therapies using a patient-derived cervical cancer xenograft model","item_type_id":"30002","owner":"1","path":["1642838231050","1642838412624"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2018-12-26"},"publish_date":"2018-12-26","publish_status":"0","recid":"2016892","relation_version_is_last":true,"title":["Evaluation of candidate therapies using a patient-derived cervical cancer xenograft model"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2025-03-11T08:37:39.700357+00:00"}